ArticleThe Eurasian journal of medicine2026
Dependency of Non-Small Cell Lung Cancer Cells on Glutamine and Glucose Levels in the Presence of Metformin.
Article in The Eurasian journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic shift is one of the hallmarks of cancer cells. Due to mutations in oncogenes such as Kirsten Rat Sarcoma Viral Oncogene (KRAS), cancer cells can adapt to stress-induced conditions. One of the adaptations that is commonly observed in non-small cell lung cancer (NSCLC) cells is glutaminolysis, where they exhibit high dependency on the presence of glutamine. Metformin is used for its anti-tumor effects, which inhibit mitochondrial complex I. This study aimed to investigate how glucose and glutamine availability affect the proliferation of three KRAS mutant NSCLC cells under metformin pressure.
methodsUsing gene expression datasets, it was observed that glutamine was the second most affected metabolite upon metformin-treated A549 cells. Based on this, several 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were done by using high and low glucose conditions having different concentrations of glutamine at different time points. Moreover, metformin was added to the setup to observe the flexibility of the cancer cells in terms of metabolic switches.
resultsAddition of glutamine resulted in a decrease in metformin's antiproliferative effect especially in high glucose conditions at later time points. A significantly higher proliferation rate in low glucose conditions compared to high glucose conditions was observed, which is especially pronounced with the addition of glutamine. These observations were supported by the gene expression analysis of the GSE dataset, which revealed upregulation of apoptosis related genes and downregulation of proliferation-related genes in metformin-treated A549 cells.
conclusionTaken together, the results highlight the importance of targeting different metabolites and metabolic pathways in cancer therapy. Cite this article as: K.ker ŞC, Tura.lı İD. Dependency of non-small cell lung cancer (NSCLC) cells on glutamine and glucose levels in the presence of metformin. Eurasian J Med. 2026, 58(2), 1018, doi:10.5152/eurasianjmed.2026.251018.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.